tetano
Editor, Senior Moderator
J Infect Dis. 2020 Mar 30. pii: jiaa150. doi: 10.1093/infdis/jiaa150. [Epub ahead of print]
Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia.
Wang F[SUP]1[/SUP], Nie J[SUP]1[/SUP], Wang H[SUP]1[/SUP], Zhao Q[SUP]1[/SUP], Xiong Y[SUP]2[/SUP], Deng L[SUP]2[/SUP], Song S[SUP]2[/SUP], Ma Z[SUP]2[/SUP], Mo P[SUP]2[/SUP], Zhang Y[SUP]2[/SUP].
Author information
Abstract
BACKGROUND:
Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. We aimed to clarify the characteristics and clinical significance of peripheral lymphocyte subset alteration in COVID-19.
METHODS:
The levels of peripheral lymphocyte subsets were measured by flow cytometry in 60 hospitalized COVID-19 patients before and after treatment, and their association with clinical characteristics and treatment efficacy was analyzed.
RESULTS:
Total lymphocytes, CD4+ T cells, CD8+ T cells, B cells and natural killer (NK) cells decreased in COVID-19 patients, and severe cases had a lower level than mild cases. The subsets showed a significant association with the inflammatory status in COVID-19, especially CD8+ T cells and CD4+/CD8+ ratio. After treatment, 37 patients (67%) reached clinical response, with an increase of CD8+ T cells and B cells. No significant change of any subset was detected in non-response cases. In multivariate analysis, post-treatment decrease of CD8+ T cells and B cells and increase of CD4+/CD8+ ratio were indicated as independent predictors for poor efficacy.
CONCLUSIONS:
Peripheral lymphocyte subset alteration was associated with the clinical characteristics and treatment efficacy of COVID-19. CD8+ T cells tended to be an independent predictor for COVID-19 severity and treatment efficacy.
? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
KEYWORDS:
COVID-19; lymphocyte subset; pneumonia
PMID:32227123DOI:10.1093/infdis/jiaa150
Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia.
Wang F[SUP]1[/SUP], Nie J[SUP]1[/SUP], Wang H[SUP]1[/SUP], Zhao Q[SUP]1[/SUP], Xiong Y[SUP]2[/SUP], Deng L[SUP]2[/SUP], Song S[SUP]2[/SUP], Ma Z[SUP]2[/SUP], Mo P[SUP]2[/SUP], Zhang Y[SUP]2[/SUP].
Author information
Abstract
BACKGROUND:
Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. We aimed to clarify the characteristics and clinical significance of peripheral lymphocyte subset alteration in COVID-19.
METHODS:
The levels of peripheral lymphocyte subsets were measured by flow cytometry in 60 hospitalized COVID-19 patients before and after treatment, and their association with clinical characteristics and treatment efficacy was analyzed.
RESULTS:
Total lymphocytes, CD4+ T cells, CD8+ T cells, B cells and natural killer (NK) cells decreased in COVID-19 patients, and severe cases had a lower level than mild cases. The subsets showed a significant association with the inflammatory status in COVID-19, especially CD8+ T cells and CD4+/CD8+ ratio. After treatment, 37 patients (67%) reached clinical response, with an increase of CD8+ T cells and B cells. No significant change of any subset was detected in non-response cases. In multivariate analysis, post-treatment decrease of CD8+ T cells and B cells and increase of CD4+/CD8+ ratio were indicated as independent predictors for poor efficacy.
CONCLUSIONS:
Peripheral lymphocyte subset alteration was associated with the clinical characteristics and treatment efficacy of COVID-19. CD8+ T cells tended to be an independent predictor for COVID-19 severity and treatment efficacy.
? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
KEYWORDS:
COVID-19; lymphocyte subset; pneumonia
PMID:32227123DOI:10.1093/infdis/jiaa150